Chemoradiotherapy in Elderly Patients With Non–Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301)
| Autor: | Takashi Seto, Hiroaki Okamoto, Miyako Satouchi, Hiroshi Tanaka, Masao Harada, Keisuke Tomii, Kazuma Kishi, Toshiyuki Sawa, Yuichiro Ohe, Naoyuki Nogami, Junki Mizusawa, Koichi Goto, Yuka Fujita, Takashi Kasai, Yuichiro Takeda, Koji Takeda, Shinji Atagi, Toshiaki Takahashi, Kazuhiko Nakagawa, Satoshi Ishikura |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Pulmonary and Respiratory Medicine Oncology Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Adenocarcinoma law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans Lung cancer Adverse effect Aged Aged 80 and over business.industry Hazard ratio Chemoradiotherapy Prognosis medicine.disease Confidence interval Carboplatin Survival Rate Radiation therapy 030104 developmental biology chemistry 030220 oncology & carcinogenesis Carcinoma Squamous Cell Carcinoma Large Cell Female business Follow-Up Studies |
| Zdroj: | Clinical Lung Cancer. 19:e619-e627 |
| ISSN: | 1525-7304 |
| Popis: | Introduction In the phase III JCOG0301 trial, chemoradiotherapy (CRT) with daily low-dose carboplatin showed significant benefits in elderly patients with locally advanced non–small-cell lung cancer (NSCLC) compared with radiotherapy (RT) alone. However, the long-term patterns and cumulative incidences of toxicity associated with CRT and RT in elderly patients are not well elucidated. We report long-term survival data and late toxicities after a minimum follow-up of 6.4 years. Patients and Methods Eligible patients were older than 70 years and had unresectable stage III NSCLC. They were randomly assigned to RT or CRT. Prognosis and adverse events data were collected beyond those in the initial report. Late toxicities were defined as occurring more than 90 days after RT initiation. Results From September 2003 to May 2010, 200 patients (RT arm, n = 100; CRT arm, n = 100) were enrolled. Consistent with the initial report, the CRT arm had better overall survival than the RT arm (hazard ratio, 0.743; 95% confidence interval, 0.552-0.998; 1-sided P = .0239). The proportion of Grade 3/4 late toxicities were 7.4% (heart 2.1%, lung 5.3%) in the RT arm (n = 94) and 7.5% (esophagus 1.1%, lung 6.5%) in the CRT arm (n = 93). No additional cases of late toxicity (Grade 3/4) and treatment-related death have been seen since the initial report that was published. Conclusion Long-term follow-up confirmed the survival benefits of CRT for elderly patients with locally advanced NSCLC. There was no observed increase in late toxicity with CRT compared with RT alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect